FTY720 (known as Fingolimod or Gilenya) functions as a high-affinity agonist of four of the five known S1PRs (except for S1PR2) and employs strong anti-inflammatory effects, received approval in 2010 to be used as immunomodulatory drug for multiple sclerosis 66, 67. This evidence concerns the gene S1PR2 and multiple sclerosis.